What Roche does

Roche Holding AG (operating as F. Hoffmann-La Roche Ltd) is a Basel-headquartered Swiss multinational that operates one of the world's largest integrated pharmaceutical and diagnostics businesses. The Pharmaceuticals division develops and commercializes prescription drugs across oncology, neurology, ophthalmology, immunology, infectious diseases, and rare diseases, serving patients across more than 200 cancer types and conditions that collectively represent roughly half of the projected 2035 global disease burden. The Diagnostics division manufactures and sells IVD instruments, reagents, and companion diagnostic assays — including the cobas 5800/6800/8800 molecular systems, LightCycler real-time PCR platforms, and VENTANA immunohistochemistry assays — to hospitals, clinical laboratories, and pathology centers. Three autonomous R&D engines (pRED in Europe, gRED at Genentech in South San Francisco, Chugai in Japan) and operating subsidiaries Foundation Medicine (molecular profiling), TIB Molbiol (rapid-response PCR assay development), Spark Therapeutics (gene therapy), and the pending PathAI (digital pathology/AI) form the technology and commercial backbone.

Roche's underlying technology platforms center on engineered biologics — CrossMab bispecific antibody technology combined with Genentech's 1997 knob-into-hole assembly system enables reliable bispecific self-assembly — and on the PD1-IL2v cancer immunotherapy platform, which restores the CD25 receptor interaction lost in earlier IL-2 variants while preserving safety. Companion diagnostic assets are technically differentiated and include the first FDA-approved IHC companion diagnostic for PTEN protein loss in prostate adenocarcinoma (VENTANA PTEN SP218 RxDx, paired with AstraZeneca's Truqap), the first AI-driven companion diagnostic for NSCLC (VENTANA TROP2 RxDx, FDA breakthrough designation April 2025), and the EU IVDR-approved VENTANA MMR RxDx Panel across five cancer types. Roche claims its Basel AI/ML team is cutting drug discovery timelines in half, and the PathAI acquisition (up to $1.05 billion, announced 2026-05-25) is intended to productize AI image analysis into routine digital pathology workflows.

Roche's revenue model spans four streams: (1) prescription pharmaceutical sales through direct country-specific sales organizations and Genentech/Chugai affiliates; (2) in vitro diagnostic hardware and reagent sales to hospitals and reference labs; (3) companion diagnostic kit and assay services that pair with specific targeted therapies (VENTANA PTEN, FoundationOne CDx, VENTANA MMR RxDx); and (4) upfront payments, milestones, profit-sharing, and royalties from co-development and co-commercialization partnerships (e.g., $700M upfront plus up to $2.3B in milestones from the 2026-06-08 Nurix BTK degrader deal, 50/50 US profit split, low- to high-teens royalties ex-US; AbbVie/Genentech co-development of venetoclax). Pricing for both pharmaceuticals and diagnostics is not publicly disclosed and is negotiated country-by-country, with Most-Favoured-Nation frameworks now embedded in the 2026 US tariff exemption agreement alongside Novartis. Geographic reach is global (100+ countries), with major manufacturing commitments of $2 billion in North Carolina, €600 million in Penzberg, and $486 million over five years in South Korea, alongside a CHF 225 billion market capitalization and a 3.2% dividend yield.

Name

Roche

Legal name

F. Hoffmann-La Roche Ltd

Website

https://roche.com

Company type

Public

Founded year

1896

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Roche is a Swiss pharmaceutical and diagnostics company that develops integrated prescription medicines and companion diagnostic tests across oncology, neurology, immunology, ophthalmology, and infectious diseases, serving patients in 100+ countries through 90,000+ employees and three autonomous R&D engines (pRED, gRED/Genentech, Chugai).

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

Keywords

• Prescription pharmaceuticals
• In vitro diagnostics
• Companion diagnostics
• Cancer immunotherapy
• Digital pathology

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals Sales: Roche sells proprietary prescription drugs through its Pharmaceuticals division across oncology, neurology, ophthalmology, immunology, infectious diseases, and other therapeutic areas, generating the majority of group revenue.
2. In Vitro Diagnostics Sales: Roche sells diagnostic instruments, reagents, and companion diagnostic kits (cobas systems, LightCycler, VENTANA IHC assays, etc.) to hospitals, clinical laboratories, and research institutions worldwide.
3. Strategic Collaboration and Licensing Revenue: Roche generates upfront payments, milestone payments, and profit-sharing revenue from co-development and co-commercialization partnerships (e.g., $700M upfront from Nurix deal, up to $2.3B in potential milestones; 40/60 development cost split; 50/50 U.S. profit split; low- to high-teens royalties on ex-U.S. sales).
4. Companion Diagnostic Services and Reagents: Recurring revenue from companion diagnostic kits and assay services that pair with specific targeted therapies (e.g., VENTANA PTEN assay paired with Truqap, FoundationOne CDx).
5. Digital Pathology and AI Diagnostics Revenue: Revenue from digital pathology platforms, AI-driven diagnostic tools, and laboratory information systems for clinical and research use.

Pricing tiers

Go-to-market motion5 records

Distribution channels6 records

Marketing channels8 records

Core offering

Roche is a Swiss pharmaceutical and diagnostics company that develops, manufactures, and sells proprietary prescription medicines (with primary focus on oncology, neurology, ophthalmology, immunology, infectious diseases, and cardiometabolic conditions) alongside in vitro diagnostic instruments, reagents, and companion diagnostic kits. Its two divisions — Pharmaceuticals and Diagnostics — operate under one roof, enabling paired therapy and companion diagnostic development; the Pharmaceuticals division is supported by three autonomous R&D engines (pRED in Europe, gRED at Genentech in the US, and Chugai in Japan), while the Diagnostics division spans molecular (cobas, LightCycler), tissue (VENTANA IHC), digital pathology, and genomic profiling (Foundation Medicine).

Differentiator

Problem solved

Functional benefit

Brands

• Genentech: US-based biopharmaceutical subsidiary focusing on R&D (gRED - Research and Early Development) and oncology products such as Tecentriq, Lunsumio, and Polivy.
• Chugai Pharmaceutical Co., Ltd.
• Foundation Medicine
• TIB Molbiol
• PathAI
• VENTANA
• cobas
• LightCycler

Products and services

• Tecentriq (atezolizumab) Genentech/Roche anti-PD-L1 cancer immunotherapy approved for multiple oncology indications including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and others; under FDA priority review for stage III dMMR/MSI-H colon cancer based on Phase III ATOMIC trial.
• Polivy (polatuzumab vedotin) Roche/Genentech antibody-drug conjugate targeting CD79b for diffuse large B-cell lymphoma (DLBCL); used in combination regimens such as Lunsumio VELO + Polivy in relapsed/refractory LBCL.
• Lunsumio (mosunetuzumab) Roche/Genentech CD20xCD3 bispecific antibody for follicular lymphoma and relapsed/refractory large B-cell lymphoma; given in fixed-duration regimens.
• Venclexta / Venclyxto (venetoclax) BCL-2 inhibitor co-developed by AbbVie and Roche/Genentech for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia; approved in more than 80 countries.
• Avastin (bevacizumab) Roche anti-VEGF monoclonal antibody used across multiple oncology indications (colorectal, lung, glioblastoma, renal, ovarian, cervical); Japan expanded use into NF2.
• Giredestrant Roche oral selective estrogen receptor degrader (SERD) for breast cancer under FDA priority review based on Phase III data showing 30% reduction in disease recurrence risk.
• Fenebrutinib Roche investigational oral BTK inhibitor in Phase III development for multiple sclerosis and other indications.
• VENTANA PTEN (SP218) RxDx Assay First FDA-approved immunohistochemistry companion diagnostic to assess PTEN protein loss in prostate adenocarcinoma, identifying patients eligible for AstraZeneca's TRUQAP (capivasertib) combination therapy with abiraterone; about 25% of metastatic hormone-sensitive prostate cancer patients have PTEN-deficient tumors.
• VENTANA MMR RxDx Panel EU IVDR-approved immunohistochemistry companion diagnostic evaluating mismatch repair (MMR) protein status in tumors to identify patients eligible for precision oncology therapies across multiple solid tumor types.
• VENTANA TROP2 RxDx (AI-powered companion diagnostic) First AI-driven companion diagnostic approved for non-small cell lung cancer, designed to identify patients who may benefit from AstraZeneca and Daiichi Sankyo's ADC Datroway.
• cobas 5800 / 6800 / 8800 molecular diagnostic systems Roche automated molecular diagnostic instrument platforms for high-throughput nucleic acid testing (PCR) in clinical laboratories, used for infectious disease testing, blood screening, and companion diagnostic workflows.
• LightCycler real-time PCR systems Roche real-time PCR instrument platform used with TIB MOLBIOL rapid-response assays for research and clinical molecular diagnostics, including emerging pathogen detection.
• navify Algorithm Suite (Liver Disease Panel) Comprehensive suite of certified algorithms including LiverPRO (Evido collaboration) supporting biomarker-based identification and management of chronic liver disease and early fibrosis risk detection.
• Roche CE-marked blood-based Alzheimer's biomarker test Roche blood-based biomarker test offered through Scottish Brain Sciences laboratory for Alzheimer's disease detection; reduces reliance on PET scan evaluations.
• Foundation Medicine genomic profiling services Roche Group affiliate providing molecular profiling services (e.g., FoundationOne CDx) used as companion diagnostics to guide targeted therapy selection across oncology.
• Petrelintide (amylin analog) Investigational amylin analog co-developed by Roche and Zealand Pharma for chronic weight management; Phase II ZUPREME-1 showed 10.7% body weight reduction at 42 weeks with placebo-like tolerability.
• Enicepatide (GLP-1/GIP dual agonist) Roche investigational GLP-1/GIP dual agonist for obesity; mid-stage trial showed 22.7% weight loss after 48 weeks.
• Bexobrutideg (NX-5948) Investigational oral BTK degrader being co-developed with Nurix Therapeutics for B-cell malignancies, immunology, and neurology indications including CLL, MS, and CSU; Phase 3 in second-line CLL planned for summer 2026.

Quantifiable outcome

• Phase III SUNMO study: Lunsumio VELO + Polivy reduced risk of disease progression or death by 59% vs R-GemOx in relapsed/refractory LBCL
• +8 more outcomes

Named customers9 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

28 partnerships are on record, tiered minor, core and flagship.

• SwissCham MexicominorGTM or Marketing Partner · 25 June 2026Roche is among major Swiss multinationals (Novartis, Nestlé, ABB, Schindler, Holcim, Zurich Insurance, Swiss Re) operating in Mexico with planned Swiss investments of $1,240 million for 2024; Swiss foreign direct investment in Mexico totaled over $12 billion between 1999 and 2025.
• North Carolina Life Sciences Organization (NCLifeSci)minorStrategic or Co-development Partner · 23 June 2026Roche joined J&J, Eli Lilly, and academic institutions in NCLifeSci's Biotech Manufacturers Forum to develop talent pipelines, following Roche's $2 billion commitment to construct new manufacturing facilities in North Carolina.
• Spark Therapeutics (acquisition legacy)minorStrategic or Co-development Partner · 23 June 2026Roche acquired Spark Therapeutics in a $4.8 billion deal; former CEO Ron Philip led Spark during the acquisition and now serves on Avalo Therapeutics' board.
• LuNGS Alliance (AstraZeneca, BMS, Eli Lilly, J&J, Pfizer)minorGTM or Marketing Partner · 20 June 2026Collaboration with oncologists, government hospitals, pharma companies (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche), Tata Capital, and startup 4baseCare to provide free NGS tests to lung cancer patients in India, with 6,600+ tests across 700 cities since March 2025.
• IAEA (Rays of Hope cancer care initiative)coreStrategic or Co-development Partner · 20 June 2026Partnership in the IAEA's Rays of Hope cancer care initiative alongside MD Anderson Cancer Center, St. Jude Children's Research Hospital, GE HealthCare, and Siemens Healthineers, helping deliver training, technology, and expertise to countries with limited access to radiotherapy and medical imaging services.
• U.S. government (pharma tariff exemption)coreStrategic or Co-development Partner · 20 June 2026Roche and Novartis have secured three-year tariff exemptions by committing to price new medicines at Most-Favored-Nation levels and announcing multi-billion-dollar investments in U.S. manufacturing facilities.
• Michael J. Fox Foundation / Neuron23minorStrategic or Co-development Partner · 17 June 2026Roche Information Solutions is providing digital biomarker technology to monitor motor and non-motor symptoms in Neuron23's NEULARK Phase 2 trial, which received a $2.5M grant from The Michael J. Fox Foundation.
• Swiss Lifesciences-Standort task forceminorStrategic or Co-development Partner · 17 June 2026Roche Schweiz participates in the Swiss federal working group 'Lifesciences-Standort' alongside Lonza, Novartis Schweiz, Scienceindustries, and Interpharma, navigating MFN pricing policy in the U.S. and Swiss drug pricing.
• Zealand PharmacoreStrategic or Co-development Partner · 15 June 2026Roche and Zealand Pharma are advancing petrelintide (amylin analog) into Phase 3 trials for chronic weight management in the second half of 2026, following Phase 2 ZUPREME-1 results showing 10.7% weight reduction at 42 weeks.
• PathAIflagshipStrategic or Co-development Partner · 12 June 2026Roche entered a definitive merger agreement to acquire PathAI for up to $1.05 billion, integrating PathAI's AISight image management system and AI analysis capabilities into Roche's Diagnostics division to enhance digital pathology workflows and advance personalized healthcare.
• AbbVie (venetoclax) - regulatory approval partnershipcoreStrategic or Co-development Partner · 12 June 2026AbbVie and Roche (Genentech) co-develop and jointly commercialize venetoclax; nine-year Phase 3 CLL14 trial results presented at EHA 2026.
• C4 TherapeuticsminorStrategic or Co-development Partner · 11 June 2026Expanded collaboration with Roche to develop degrader-antibody conjugates for oncology, including a $20 million upfront payment and potential milestone payments exceeding $1 billion.
• Monte Rosa TherapeuticscoreStrategic or Co-development Partner · 11 June 2026Strategic partnership worth over $2 billion for Monte Rosa's molecular glue degrader platform, complementing an additional up to $5.7B partnership with Novartis.
• Nurix TherapeuticsflagshipStrategic or Co-development Partner · 8 June 2026Global collaboration to co-develop and co-commercialize bexobrutideg (NX-5948), an investigational oral BTK degrader for B-cell malignancies, immunology, and neurology indications including CLL, MS, and CSU. Nurix receives $700M upfront with up to $2.3B in total milestones; development costs split 40% Nurix / 60% Roche; 50/50 U.S. profit split; low- to high-teens royalties on ex-U.S. sales; Phase 3 in second-line CLL planned for summer 2026.
• AbbVie / Genentech (venetoclax)coreStrategic or Co-development Partner · 8 June 2026Venetoclax (VENCLEXTA/VENCLYXTO) is co-developed by AbbVie and Roche, jointly commercialized with Genentech in the U.S. and by AbbVie outside the U.S., and approved in more than 80 countries for multiple CLL indications.
• Monte Rosa Therapeutics (Roche + Novartis deals)minorStrategic or Co-development Partner · 8 June 2026Part of the wave of molecular glue deal activity; Monte Rosa signed deals potentially worth over $10 billion with multiple pharma including Roche, Novartis, and others.
• IDEAYA BiosciencesminorStrategic or Co-development Partner · 3 June 2026Clinical collaboration to evaluate IDE892 (IDEAYA's PRMT5 inhibitor) in combination with Roche's pan-RAS inhibitor RG6505 in pancreatic ductal adenocarcinoma with MTAP deletion and RAS mutation.
• AstraZeneca (Truqap companion diagnostic)coreStrategic or Co-development Partner · 2 June 2026Roche's VENTANA PTEN (SP218) RxDx Assay identifies patients eligible for AstraZeneca's TRUQAP (capivasertib) combination therapy with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer, based on CAPItello-281 trial results.
• South Korea (national commitment)minorStrategic or Co-development Partner · 27 May 2026Roche committed $486 million over five years to expand clinical trials and support Korean biotech ventures, supporting Seoul's ambition to become a top global biopharma power by 2030.
• Recursion PharmaceuticalsminorStrategic or Co-development Partner · 27 May 2026Recursion Pharmaceuticals forms partnerships with industry leaders including Nvidia, Roche, Sanofi, and Bayer, leveraging AI and machine learning through its Recursion OS platform to enhance drug development.
• U.S. government (tariff agreement)coreStrategic or Co-development Partner · 27 May 2026Roche among Swiss firms committed to at least $200 billion in U.S. investment, including $67 billion in 2026, under framework reducing U.S. tariff rate on Swiss exports from 39% to 15%.
• Apmarr - Associazione nazionale persone con malattie reumatologiche e rare (Italian survey)minorGTM or Marketing Partner · 27 May 2026Roche and Celltrion are funding a project called 'Patologie reumatologiche in Italia – Epidemiologia ed equità di accesso alle cure' that includes a national survey on lupus erythematosus and lupus nephritis in Italy, conducted in collaboration with Crea Sanità.
• Slovenia (national engagement)minorStrategic or Co-development Partner · 26 May 2026Slovenian President Pirc Musar met with Roche executives during an official visit to Switzerland to discuss expanding pharmaceutical investment in Slovenia.
• Atalanta TherapeuticsminorStrategic or Co-development Partner · 1 January 2024Collaboration entails the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. Atalanta launched with $110 million to pioneer RNAi therapeutics.
• Ionis PharmaceuticalsminorStrategic or Co-development Partner · 1 January 2024Early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD).
• Sangamo TherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 1 January 2024Exclusive license to Sangamo's proprietary zinc finger repressors directed to the tau gene, critically involved in AD and other tauopathies, as well as an undisclosed second neurology target.
• TIB Molbiol GroupcoreStrategic or Co-development Partner · 9 September 2021Acquisition of TIB Molbiol Group, expected to close in the fourth quarter of 2021, expanding Roche's molecular diagnostics portfolio especially for infectious diseases. TIB Molbiol has a long-term collaboration with Roche, notably during the COVID-19 pandemic, and is now leveraging its rapid response library of 15,000 pre-designs and 3,000 controls.
• Disc Medicine (bitopertin licensing)minorOEM/ Whitelabel/ Licensing Partner · 1 May 2021Disc Medicine obtained global rights to bitopertin (an investigational glycine transporter 1 inhibitor) from Roche in May 2021; FDA Phase 3 APOLLO study data anticipated Q4 2026 with FDA decision expected by mid-2027.

Scale indicators17 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• Novartis: Swiss-headquartered global pharmaceutical company operating in oncology, cardiovascular, immunology, and neurology with co-marketing partnership with Roche on venetoclax; comparable scale, business model, and Swiss listing make it the closest direct peer.
• Merck & Co. U.S.-based pharmaceutical company with leading oncology (Keytruda) franchise; competing head-to-head with Roche in oncology and benefiting from Roche's VENTANA MMR RxDx Panel to identify Keytruda-eligible patients.
• AstraZeneca: Global biopharmaceutical company with deep oncology and cardiometabolic pipelines; partners with Roche on companion diagnostics (TRUQAP/TROP2) and competes in ADC and targeted oncology.
• Pfizer: One of the largest global pharmaceutical companies with broad oncology, immunology, and rare disease portfolios; comparable in scale and therapeutic area breadth to Roche.
• Eli Lilly: Global pharmaceutical leader in cardiometabolic/obesity (Mounjaro, Zepbound), oncology, and immunology; directly competes with Roche's emerging obesity and cardiometabolic pipeline.
• AbbVie: Global biopharmaceutical company with leading immunology and oncology franchises; co-develops and co-commercializes venetoclax with Roche/Genentech and competes in hematology.
• Bristol Myers Squibb: U.S. global biopharma with leading oncology and hematology franchises (Revlimid, Opdivo); comparable scale and therapeutic focus, and LuNGS Alliance partner with Roche in India.
• Sanofi: Global pharmaceutical company with immunology (Dupixent), rare disease, and vaccines focus; comparable European footprint and directly competing in immunology and rare diseases.
• GSK: British global pharmaceutical company with oncology, vaccines, and specialty medicines portfolios; competes with Roche in oncology and benefits from Roche VENTANA MMR RxDx Panel for JEMPERLI patient identification.

Broad incumbents

• Thermo Fisher Scientific: Global life sciences and diagnostics conglomerate with broad instruments, reagents, and clinical diagnostics offerings; competes with Roche's diagnostics division across IVD and serves as a broader tools/IVD incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat8 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Roche
• YouTubeyoutube.com/roche
• Facebookfacebook.com/RocheCareers
• LinkedInlinkedin.com/company/roche
• Instagraminstagram.com/roche

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries7 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A58 records

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche